C-Abl antagonizes the YAP oncogenic function

Cell Death and Differentiation

Volumn 22, Issue 6, 2015, Pages 935-945

  Keshet, R ^a   Adler, J ^a   Ricardo Lax, I ^a   Shanzer, M ^a   Porat, Z ^a   Reuven, N ^a   Shaul, Y ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; PROTEIN BINDING; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TEAD1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

CELL LINE; DNA DAMAGE; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOPRECIPITATION; METABOLISM; ONCOGENE; PHOSPHORYLATION; PHYSIOLOGY; WESTERN BLOTTING; WOUND HEALING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BLOTTING, WESTERN; CELL LINE; DNA DAMAGE; DNA-BINDING PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENES, ABL; HUMANS; IMMUNOPRECIPITATION; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN BINDING; TRANSCRIPTION FACTORS; WOUND HEALING;

EID: 84939989486     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.182     Document Type: Article

References (45)

1. Harvey K, Tapon N. The Salvador-Warts-Hippo pathway-an emerging tumour-suppressor network. Nat Rev 2007; 7: 182-191.
2. Pan D. Hippo signaling in organ size control. Genes Dev 2007; 21: 886-897.
3. Saucedo LJ, Edgar BA. Filling out the Hippo pathway. Nat Rev Mol Cell Biol 2007; 8: 613-621.
4. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007; 17: 2054-2060.
5. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007; 130: 1120-1133.
6. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21: 2747-2761.
7. Sudol M, Harvey KF. Modularity in the Hippo signaling pathway. Trends Biochem Sci 2010; 35: 627-633.
8. Salah Z, Aqeilan RI. WW domain interactions regulate the Hippo tumor suppressor pathway. Cell Death Dis 2011; 2: E172.
9. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 2010; 24: 72-85.
10. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008; 283: 5496-5509.
11. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 1986; 47: 277-284.
12. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997; 387: 516-519.
13. Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 1999; 399: 809-813.
14. Yuan ZM, Huang Y, Whang Y, Sawyers C, Weichselbaum R, Kharbanda S et al. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature 1996; 382: 272-274.
15. Goldberg Z, Vogt Sionov R, Berger M, Zwang Y, Perets R, Van Etten RA et al. Tyrosine phosphorylation of Mdm2 by c-Abl: Implications for p53 regulation. EMBO J 2002; 21: 3715-3727.
16. Allington TM, Galliher-Beckley AJ, Schiemann WP. Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors. FASEB J 2009; 23: 4231-4243.
17. Guo J, Kleeff J, Zhao Y, Li J, Giese T, Esposito I et al. Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma. Int J Mol Med 2006; 17: 761-767.
18. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006; 103: 12405-12410.
19. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125: 1253-1267.
20. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
21. Zhao B, Ye X, Yu J, Li L, Li W, Li S et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008; 22: 1962-1971.
22. Zhang H, Pasolli HA, Fuchs E. Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin. Proc Natl Acad Sci USA 2011; 108: 2270-2275.
23. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 2001; 276: 15164-15173.
24. Levy D, Adamovich Y, Reuven N, Shaul Y. Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol Cell 2008; 29: 350-361.
25. Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ et al. beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 2012; 151: 1457-1473.
26. Levy D, Adamovich Y, Reuven N, Shaul Y. The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ 2007; 14: 743-751.
27. Davidson I, Xiao JH, Rosales R, Staub A, Chambon P. The HeLa cell protein TEF-1 binds specifically and cooperatively to two SV40 enhancer motifs of unrelated sequence. Cell 1988; 54: 931-942.
28. Pluk H, Dorey K, Superti-Furga G. Autoinhibition of c-Abl. Cell 2002; 108: 247-259.
29. Taagepera S, McDonald D, Loeb JE, Whitaker LL, McElroy AK, Wang JY et al. Nuclearcytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci USA 1998; 95: 7457-7462.
30. Zaidi SK, Sullivan AJ, Medina R, Ito Y, Van Wijnen AJ, Stein JL et al. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 2004; 23: 790-799.
31. Wang MY, Chen PS, Prakash E, Hsu HC, Huang HY, Lin MT et al. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res 2009; 69: 3482-3491.
32. Reuven N, Adler J, Meltser V, Shaul Y. The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl. Cell Death Differ 2013; 20: 1330-1340.
33. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M et al. Role of YAP/TAZ in mechanotransduction. Nature 2011; 474: 179-183.
34. Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N et al. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol 2012; 14: 1322-1329.
35. Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA et al. The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell 2010; 18: 579-591.
36. Fujii M, Nakanishi H, Toyoda T, Tanaka I, Kondo Y, Osada H et al. Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFbeta signaling and defects in the Hippo signaling cascade. Cell Cycle 2012; 11: 3373-3379.
37. Poernbacher I, Baumgartner R, Marada SK, Edwards K, Stocker H. Drosophila Pez acts in Hippo signaling to restrict intestinal stem cell proliferation. Curr Biol 2012; 22: 389-396.
38. Wang W, Huang J, Wang X, Yuan J, Li X, Feng L et al. PTPN14 is required for the densitydependent control of YAP1. Genes Dev 2012; 26: 1959-1971.
39. Liu X, Yang N, Figel SA, Wilson KE, Morrison CD, Gelman IH et al. PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene 2013; 32: 1266-1273.
40. Huang JM, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A et al. YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the nonreceptor type protein tyrosine phosphatase 14. Oncogene 2013; 32: 2220-2229.
41. Michaloglou C, Lehmann W, Martin T, Delaunay C, Hueber A, Barys L et al. The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity. PLoS One 2013; 8: E61916.
42. Tsutsumi R, Masoudi M, Takahashi A, Fujii Y, Hayashi T, Kikuchi I et al. YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function. Dev Cell 2013; 26: 658-665.
43. Wadham C, Gamble JR, Vadas MA, Khew-Goodall Y. Translocation of protein tyrosine phosphatase Pez/PTPD2/PTP36 to the nucleus is associated with induction of cell proliferation. J Cell Sci 2000; 113(Pt 17): 3117-3123.
44. Haviv I, Shamay M, Doitsh G, Shaul Y. Hepatitis B virus pX targets TFIIB in transcription coactivation. Mol Cell Biol 1998; 18: 1562-1569.
45. Morgenstern JP, Land H. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3587-3596.